NCT05576181

A Single Dose-escalation Study to Evaluate the Safety and Efficacy of Allogeneic CAR-T Targeting CD19 Bridging Hematopoietic Stem Cell Transplantation in Patients With Refractory or Relapsed B Cell Acute Lymphoblastic Leukemia

Study Summary

This is a a phase 1, open label study to assess the safety and efficacy of ThisCART19 (Allogeneic CAR-T targeting CD19) Bridging Hematopoietic Stem Cell Transplantation in patients with refractory or relapsed B cell acute lymphoblastic leukemia (r/r B-ALL).

Want to learn more about this trial?

Request More Info

Interventions

ThisCART19ADRUG
ThisCART19A is a new type CAR-T therapy for patients with r/r B-ALL.
Fludarabine Oral TabletDRUG
Fludarabine is used for lymphodepletion.
CyclophosphamideDRUG
Cyclophosphamide is used for lymphodepletion.
VP-16DRUG
VP-16 is used for lymphodepletion.
HSCTPROCEDURE
Hematological stem cell transplantation

Study Locations

No locations listed.

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026